GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Other Stockholders Equity

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Other Stockholders Equity : CHF34.6 Mil (As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Other Stockholders Equity?

Cosmo Pharmaceuticals NV's Other Stockholders Equity for the quarter that ended in Jun. 2023 was CHF34.6 Mil.

Cosmo Pharmaceuticals NV's quarterly Other Stockholders Equity declined from Jun. 2022 (CHF46.6 Mil) to Dec. 2022 (CHF35.9 Mil) and declined from Dec. 2022 (CHF35.9 Mil) to Jun. 2023 (CHF34.6 Mil).

Cosmo Pharmaceuticals NV's annual Other Stockholders Equity declined from Dec. 2020 (CHF103.6 Mil) to Dec. 2021 (CHF30.6 Mil) but then increased from Dec. 2021 (CHF30.6 Mil) to Dec. 2022 (CHF35.9 Mil).


Cosmo Pharmaceuticals NV Other Stockholders Equity Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Other Stockholders Equity Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.21 83.66 103.56 30.59 35.87

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.91 30.59 46.62 35.87 34.60

Cosmo Pharmaceuticals NV Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Cosmo Pharmaceuticals NV Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines